Steady-State Amprenavir, Tenofovir, and Emtricitabine Pharmacokinetics Before and After Reducing Ritonavir Boosting of a Fosamprenavir/Tenofovir/Emtricitabine Regimen from 200 mg to 100 mg Once Daily (TELEX II)

REFERENCES

• Wire MB, Shelton MJ, Studenberg S. Fosamprenavir. Clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet. 2006;45: 137–168.
   PubMed Web of Science ®Google Scholar
• Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumar-ate. Clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43:595–612.
   PubMed Web of Science ®Google Scholar
• Bang LM, Scott U. Emtricitabine. An antiretroviral agent for HIV infection. Drugs. 2003;63:2413–2424.
   PubMed Web of Science ®Google Scholar
• Cooper CL, van Heeswijk RPG, Gallicano K, Cameron DW. A review of low-dose ritonavir in protease inhibitor combi-nation therapy. Clin Infect Dis. 2003;36:1585–1592.
   PubMed Web of Science ®Google Scholar
• Gathe JC Jr, Lye P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS. 2004;18:1529–1537.
   PubMed Web of Science ®Google Scholar
• Smith KY, Weinberg WG, DeJesus E, et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther 2008;5(5):1–10.
   PubMedGoogle Scholar
• DeJesus E, Sloan L, Sension M, et al. 96-week efficacy/safety data comparing two doses of ritonavir (/r) to boost once-daily (QD) fosamprenavir (FPV), used in combination with abacavir (ABC)/lamivudine (3TC). In : Program and abstracts of the Interscience Conference on Antimicrobial Agents and Che-motherapy (ICAAC) 48th Annual Meeting/Infectious Diseases Society of America/46th Annual Meeting; October 25–28, 2008; Washington, DC. Abstract/Poster H–1246.
   Google Scholar
• Hsu R, Walker-Reed K, Acosta E. Fosamprenavir (FPV) with low-dose ritonavir (RTV) once-daily (QD) in HIV-infected subjects. In: Program and abstracts of the 7th International Workshop on Clinical Pharmacology of HIV Therapy; April 20–22, 2006; Lisbon, Portugal. Abstract/poster 71.
   Google Scholar
• Ruane PJ, Luber AD, Wire MB, et al. Plasma amprenavir pharmacokinetics and tolerability following administra-tion of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. Antimicrob Agents Chemother. 2007;51:560–565.
   PubMed Web of Science ®Google Scholar
• Garraffo R, Lavrut T, Heripret I, et al. Fosamprenavir (FPV) trough concentrations (C.n) and inhibitory quotients (IQ), at steady-state, in plasma and lymphocytes of HIV infected patients receiving different dosage regimens. In: Program and abstracts of the 6th International Workshop on Clinical Pharmacology of HIV Therapy; April 28–30 2005; Quebec City (QC). Abstract 5, Poster 1.5.
   Google Scholar
• DeWit S, Poll B, Necsoi C, Clumeck N. Fosamprenavir boosted with a single 100 mg capsule of ritonavir as part of a once daily first line regimen in naïve patients. In: Pro-gram and abstracts of the 8th International Congress on Drug Therapy in HIV Infection; November 12–16, 2006; Glasgow, United Kingdom. Abstract/poster P17.
   Google Scholar
• Muret P, Muret P, Montange D, et al. Assessment of ampre-navir plasma Crn,r, levels in patients receiving once-daily fosamprenavir in combination with either 100 or 200 mg ritonavir. In: Program and abstracts from Congres P2T Physiology, Pharmacology and Therapeutics; April 2007; Toulouse, France. Abstract 216.
   Google Scholar
• FDA approves administration of LEXIVA with lower dose of "boosting" medication ritonavir [press release]. October 12, 2007.Availableat http://us.gsk.com/ControllerSerylet?appld=4&pageld=402&newsid=1158.
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adoles-cents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; 1–139. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed February 3, 2009.
   Google Scholar
• Parks DA, Jennings HC, Taylor CW, et al. Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosampre-navir in HIV-infected subjects. AIDS. 2007;21:1373–1375.
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clear-ance from serum creatinine. Nephron. 1976;16:31–41.
   PubMed Web of Science ®Google Scholar
• Sale M, Sadler BM, Stein DS. Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir. Antimicrob Agents Chemother 2002;46:746–754.
   PubMed Web of Science ®Google Scholar
• Kurowski M. Influence of 50 mg, 100 mg, and 200 mg ritonavir (RTV) on the pharmacokinetics (PK) of amprenavir (APV) after multiple doses in healthy volunteers for once daily (QD) and twice daily (BID) regimens. In: Program and abstracts of the First International AIDS Society Confer-ence on HIV Pathogenesis and Treatment; July 8–11, 2001; Buenos Aires, Argentina. Abstract 351.
   Google Scholar
• Kilby JM, Hill A, Buss N. The effect of ritonavir on saquina-vir plasma concentration is independent of ritonavir dos-age: combined analysis of pharmacokinetic data from 97 subjects. HIV Med. 2002;3:97–104.
   PubMedGoogle Scholar
• Shelton MJ, Wire MB, Lou Y, et al. Pharmacokinetic and safety evaluation of high-dose combinations of fosam-prenavir and ritonavir. Antimicrob Agents Chemother. 2006;50:928–934.
   PubMed Web of Science ®Google Scholar
• Luber A, Slowinski D, Andrews M, et al. Steady-state phar-macokinetics (PK) of tenofovir (TDF) and fosamprenavir (FPV) after once daily (QD) TDF with unboosted or ritonavir (R)-boosted twice daily (BID) FPV in healthy volunteers. In: Program and abstracts of the 8th International Congress of Drug Therapy and HIV Infection; November 12–16, 2006; Glasgow, UK. Abstract/Poster P274.
   Google Scholar
• Kurowski M, Walli RK, Breske A, et al. Fosamprenavir/ ritonavir does not affect amprenavir pharmacokinetics: no effect of tenofovir. AIDS. 2007;21:1368–1370.
   PubMed Web of Science ®Google Scholar
• DeJesus E, Lamarca A, Sension M, et al. The CONTEXT study: efficacy and safety of GW433908/RTV in P1-experienced subjects with virological failure-24-week results. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10–14, 2003; Boston, MA. Abstract/presentation 178.
   Google Scholar
• Zong J, Chittick GE, Wang LH, Hui J, Begley JA, Blum MR. Pharmacokinetic evaluation of emtricitabine in combina-tion with other nucleoside antivirals in healthy volunteers. J Clin Pharmacol. 2007;47:877–889.
   PubMed Web of Science ®Google Scholar
• Wang LH, Begley J, St Claire RL, et al. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infec-tion. AIDS Res Hum Retroviruses. 2004;20:1173–1182.
   PubMed Web of Science ®Google Scholar
• Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2001;45:2733–2739.
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Shen G, Cheng A, et al. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coed-ministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. J Acquir Immune Defic Syndr 2007;45:274–279.
   PubMed Web of Science ®Google Scholar
• Ray AS, Tong L, Robinson KL, et al. Role of intestinal absorption in increased tenofovir exposure when tenofovir disoproxil fumarate is co-administered with atazanavir or lopinavir/ritonavir. In: Program and abstracts of the 7th International Workshop on Clinical Pharmacology of HIV Therapy; April 20–22, 2006; Lisbon, Portugal. Abstract 49.
   Google Scholar